All In Biotech

Drug Trial Radar · NCT05485753

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of Tetra-specific Antibody GNC-038 Injection in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7

Actual

Start

Feb 10, 2023

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
Collaborators
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Aug 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this study, the safety and preliminary efficacy of GNC-038 in patients with r relapsed or refractory primary central nervous system lymphoma (PCNSL) and relapsed or refractory secondary central nervous system lymphoma (SCNSL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.

Conditions

  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma

Interventions

  • GNC-038Drug

    Administration by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: Up to 17 days after the first dose
  2. Maximum tolerated dose (MTD) or maximum administrated dose (MAD)Time frame: Up to 17 days after the first dose
  3. Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 36 months
  4. The recommended dose for phase II clinical study(RP2D)Time frame: Up to 17 days after the first dose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing GoBroad Boren Hospital

    Beijing, Beijing Municipality, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.